无码欧美成人av天堂456软件,大胆日本熟妇XXXX,9277在线观看免费播放,4p三个男人让我爽了一夜

產(chǎn)品訂購信息：
英文名稱  Anti-RBPJK/RBP-J 

中文名稱   Notch轉(zhuǎn)錄調(diào)控蛋白R(shí)BPJK抗體品牌 

別    名  AI843960; CBF 1; CBF-1; CBF1; IGKJRB1; J kappa recombination signal binding protein; J kappa-recombination signal binding protein; J kappa-recombination signal-binding protein; KBF2; NY REN 30 antigen; RBP J kappa; RBP-J; RBP-J kappa; RBP-JK; Rbpj; RBPJK; RBPSUH; Recombining binding protein suppressor of hairless; Renal carcinoma antigen NY-REN-30; SUH_HUMAN.

濃    度   1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來源   Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit 

產(chǎn)品類型   一抗  

研究領(lǐng)域    染色質(zhì)和核信號(hào) 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 干細(xì)胞 轉(zhuǎn)錄調(diào)節(jié)因子 表觀遺傳學(xué)

蛋白分子量  predicted molecular weight: 56kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human RBPJK 

亞    型   IgG

純化方法   affinity purified by Protein A

儲(chǔ) 存 液   Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4

Notch轉(zhuǎn)錄調(diào)控蛋白R(shí)BPJK抗體品牌 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 Transcriptional regulator that plays a central role in Notch signaling, a signaling pathway involved in cell-cell communication that regulates a broad spectrum of cell-fate determinations. Acts as a transcriptional repressor when it is not associated with Notch proteins. When associated with some NICD product of Notch proteins (Notch intracellular domain), it acts as a transcriptional activator that activates transcription of Notch target genes. Probably represses or activates transcription via the recruitment of chromatin remodeling complexes containing histone deacetylase or histone acetylase proteins, respectively. Specifically binds to the immunoglobulin kappa-type J segment recombination signal sequence.

Function : Transcriptional regulator that plays a central role in Notch signaling, a signaling pathway involved in cell-cell communication that regulates a broad spectrum of cell-fate determinations. Acts as a transcriptional repressor when it is not associated with Notch proteins. When associated with some NICD product of Notch proteins (Notch intracellular domain), it acts as a transcriptional activator that activates transcription of Notch target genes. Probably represses or activates transcription via the recruitment of chromatin remodeling complexes containing histone deacetylase or histone acetylase proteins, respectively. Specifically binds to the immunoglobulin kappa-type J segment recombination signal sequence. Binds specifically to methylated DNA.

Subunit : Interacts with activated NOTCH1, NOTCH2 or NOTCH3. Interacts with MINT/SHARP. This interaction may mediate the recruitment of large corepressor complexes containing proteins such as HDAC1, HDAC2, NCOR2, SAP30, FHL1/KYOT2 and CIR1. Interacts with EP300, MAML1 and PTF1A. Interacts with Epstein-Barr virus EBNA2, EBNA3, EBNA4 and EBNA6. Interacts with RITA/C12orf52, leading to nuclear export, prevent the interaction between RBPJ and NICD product and subsequent down-regulation of the Notch signaling pathway. Interacts with SNW1.

Subcellular Location : Nucleus. Cytoplasm. Note=Mainly nuclear, upon interaction with RITA/C12orf52, translocates to the cytoplasm, down-regulating the Notch signaling pathway.

DISEASE : Adams-Oliver syndrome 3 (AOS3) [MIM:614814]: An autosomal dominant form of Adams-Oliver syndrome, a disorder characterized by the congenital absence of skin (aplasia cutis congenita) in combination with transverse limb defects. Aplasia cutis congenita can be located anywhere on the body, but in the vast majority of the cases, it is present on the posterior parietal region where it is often associated with an underlying defect of the parietal bones. Limb abnormalities are typically limb truncation defects affecting the distal phalanges or entire digits (true ectrodactyly). Only rarely, metatarsals/metacarpals or more proximal limb structures are also affected. Apart from transverse limb defects, syndactyly, most commonly of second and third toes, can also be observed. The clinical features are highly variable and can also include cardiovascular malformations, brain abnormalities and vascular defects such as cutis marmorata and dilated scalp veins. AOS3 patients manifest characteristic vertex scalp defects and terminal limb defects, but without congenital heart defects, other associated defects, or immune defects. Note=The disease is caused by mutations affecting the gene represented in this entry.

Similarity : Belongs to the Su(H) family.

Contains 1 IPT/TIG domain.

Database links : UniProtKB/Swiss-Prot: Q06330.3

Anti-Syntrophins/SNTA1/Syntrophin α1/FITC 熒光素標(biāo)記神經(jīng)肌肉接頭蛋白SNTA1抗體IgGMulti-class antibodies規(guī)格： 0.2ml

HEV 病毒(抗原)Multi-class antibodies規(guī)格： 0.5mg

鼠抗人特異性抗原抗體 Anti-PSA 0.2ml

STMN3 英文名稱： 原癌基因18家族STMN3蛋白抗體 0.1ml

EMR1 英文名稱： 表皮生長因子樣激素受體1抗體 0.1ml

Rhesus antibody Rh Phospho-MKK7 (Ser271/Thr275) 磷酸化原活化蛋白激酶MKK7抗體 規(guī)格 0.1ml

HEV 病毒(抗原)Multi-class antibodies規(guī)格： 0.5mg

Anti-RGS5 /FITC 熒光素標(biāo)記兔抗人G蛋白信號(hào)轉(zhuǎn)導(dǎo)調(diào)節(jié)因子5抗體IgGMulti-class antibodies規(guī)格： 0.2ml

VIP (Vasoactive Intestinal peptide) 活性腸肽Multi-class antibodies規(guī)格： 0.5mg

髓鞘相關(guān)糖蛋白-a抗體 Anti-MAG-a/L-MAG 0.1ml

SOD3 英文名稱： 超氧化物歧化酶3抗體 0.1ml

FOX C2 英文名稱： 叉頭相關(guān)轉(zhuǎn)錄因子C2抗體 0.2ml

Rhesus antibody Rh phospho-PKA beta(Ser338) 磷酸化蛋白激酶Aβ抗體 規(guī)格 0.1ml

VIP (Vasoactive Intestinal peptide) 活性腸肽Multi-class antibodies規(guī)格： 0.5mg

IL-13 大鼠白介素-13Multi-class antibodies規(guī)格： 48T

Anti-alpha Defensin 1/3 防御素α1/3抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh Nectin 3/CD113 細(xì)胞粘附分子3抗體(病毒受體相關(guān)蛋白3) 規(guī)格 0.1ml

Human Triggering Receptor Expresses on Myeloid Cells-1,TREM-1 ELISA Kit 人髓系細(xì)胞觸發(fā)受體-1 96T

SULT4A1 英文名稱： 腦磺基轉(zhuǎn)移酶樣蛋白4A1抗體 0.2ml

C1QL3 英文名稱： 補(bǔ)體C1qL3鏈多肽抗體 0.2ml

Anti-alpha Defensin 1/3 防御素α1/3抗體Multi-class antibodies規(guī)格： 0.1ml

曲霉素瓊脂基礎(chǔ)(AFPA)250g用于曲霉菌分離培養(yǎng)

ITC肉湯(基礎(chǔ)) incubation media ITC肉湯(基礎(chǔ))

10%氯胰酪胨大豆肉湯 250g 用于金黃色葡萄球菌的多管發(fā)酵法測定及增菌培養(yǎng)(GB/T4789.10-2008)。

SD大鼠脂肪間質(zhì)干細(xì)胞成軟骨誘導(dǎo)分化完全培養(yǎng)基SDratadiposemesenchymalstemcellsintochondrocytesinduceddifferentiationofcompletemedium

錳鹽營養(yǎng)瓊脂 250g 用于嗜熱需氧芽孢桿菌的檢驗(yàn)

溴化十六烷基銨瓊脂(USP)250g用于綠膿假單胞菌的分離培養(yǎng)

金黃色葡萄球菌顯色培養(yǎng)基 5000 mL/瓶 incubation media 金黃色葡萄球菌顯色培養(yǎng)基 5000 mL/瓶

李氏增菌液LB2凍干配套試劑 10支 每支添加于200ml(026040)中配成LB2增菌液。

瓊脂培養(yǎng)基OAgarmediumO(Baird-Parkeragar)用于金黃色葡萄球菌的分離培養(yǎng)。

APT瓊脂 250g 用于乳酸菌分離培養(yǎng)

Notch轉(zhuǎn)錄調(diào)控蛋白R(shí)BPJK抗體品牌 平板計(jì)數(shù)瓊脂(PCA) 1000(g)  incubation media 平板計(jì)數(shù)瓊脂(PCA) 1000(g)

假單胞分離瓊脂 250(g)  incubation media 假單胞分離瓊脂 250(g)

假單胞分離肉湯 250(g)  incubation media 假單胞分離肉湯 250(g)

假單胞F瓊脂 250(g)  incubation media 假單胞F瓊脂 250(g)

抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：

1. Notch轉(zhuǎn)錄調(diào)控蛋白R(shí)BPJK抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來篩選最適條件；

3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；

8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。

抗體的鑒定：

1）Notch轉(zhuǎn)錄調(diào)控蛋白R(shí)BPJK抗體品牌 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力。抗體的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗(yàn)測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。